Michael Unterhalt

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Eva Hoster, Martin Dreyling, Wolfram Klapper et al. · Blood · 2007 · 944 citations

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Alessandro Pastore, Vindi Jurinović, Robert Kridel et al. · The Lancet Oncology · 2015 · 608 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +9

Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)

Georg Lenz, Martin Dreyling, Eva Hoster et al. · Journal of Clinical Oncology · 2005 · 573 citations · Full text

Treatment of Older Patients with Mantle-Cell Lymphoma

Hanneke C. Kluin‐Nelemans, Eva Hoster, Olivier Hermine et al. · New England Journal of Medicine · 2012 · 511 citations · Full text

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)

Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling et al. · Blood · 2006 · 464 citations · Full text